Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs. (March 2015)

• Record Type: Journal Article
• Authors: AlDeghaither, Dalal; Smaglo, Brandon G.; Weiner, Louis M.; Korth‐Bradley, Joan; Mager, Donald; Meibohm, Bernd; Zhou, Hong Hui
• Is Part Of: Journal of clinical pharmacology. Volume 55:Number 3(2015:Mar.)
• Page Start: S4
• Page End: S20
• Publication Date: 2015-03
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.407
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph407-sec-0001" sec-type="section"> <p>Biotherapeutics are attractive anti‐cancer agents due to their high specificity and limited toxicity compared to conventional small molecules. Antibodies are widely used in cancer therapy, either directly or conjugated to a cytotoxic payload. Peptide therapies, though not as prevalent, have been utilized in hormonal therapy and imaging. The limitations associated with unmodified forms of both types of biotherapeutics have led to the design and development of novel structures, which incorporate key features and structures that have improved the molecules' abilities to bind to tumor targets, avoid degradation, and exhibit favorable pharmacokinetics. In this review, we highlight the current status of monoclonal antibodies and peptides, and provide a perspective on the future of biotherapeutics using novel constructs.</p> </sec> </abstract>